Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Peter G. Pappas(University of Alabama at Birmingham), Donald N. Buell(Astellas Pharma (Japan)), Deepak Talwar, Raghunadharao Digumarti(Heidelberg University), L Arnold(Astellas Pharma (Japan)), C. M. F. Rotstein(Hamilton Health Sciences), Laura Kovanda(Astellas Pharma (Japan)), Luis Ostrosky‐Zeichner(The University of Texas Health Science Center), Annette C. Reboli(Cooper Medical School of Rowan University), José A. Vázquez(Augusta University), David L. Horn(United States Military Academy), Robert F. Betts(Unknown), Byungse Suh(Temple University), Chunzhang Wu(Astellas Pharma (Japan)), Márcio Nucci(Universidade Federal do Rio de Janeiro), B Dupont(Hôpital Necker-Enfants Malades), Jan J. De Waele(Ghent University Hospital)
Cited by 632
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k